GAMMA Investing’s Tourmaline Bio TRML Stock Holding History

GAMMA Investing’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-570	Closed	-$27.3K	–	4138
2025 Q3	$27.3K	Buy	570 +121	+27%	+$3.36K	﹤0.01%	2363
2025 Q2	$7.18K	Sell	449 -45	-9%	-$729	﹤0.01%	2971
2025 Q1	$7.51K	Buy	494 +330	+201%	+$5.29K	﹤0.01%	2884
2024 Q4	$3.33K	Buy	164 +17	+12%	+$428	﹤0.01%	3062
2024 Q3	$3.78K	Buy	+147	New	+$2.45K	﹤0.01%	2855
2024 Q2	–	Sell	-11	Closed	-$252	–	3509
2024 Q1	$252	Buy	+11	New	+$388	﹤0.01%	3205

GAMMA Investing's TRML Position: Q4 2025 in Review

GAMMA Investing sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 570 shares — an estimated $27.3K sold.

GAMMA Investing first reported a position in TRML in Q1 2024 and held it in 6 quarters. The position peaked at $27.3K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

GAMMA Investing reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
GAMMA Investing sold 570 Tourmaline Bio shares in Q4 2025, an estimated $27.3K.
GAMMA Investing first reported a position in Tourmaline Bio in Q1 2024 and held it in 6 quarters.
GAMMA Investing's Tourmaline Bio position peaked at $27.3K in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on GAMMA Investing's 13F filing for Q4 2025, filed 5 Jan 2026.